The Precision Medicine Company

Developing microbiome-based predictive diagnostic and companion therapeutic products to enable safer and more efficacious drug therapies

AlphaBiomics’ CEO Anthony Williamson invited to speak at workshop on how the microbiome influences the therapeutic effectiveness of drugs. 

Read more here.

NIHR_Logos_Funded by_COL_CMYK

The Precision Medicine Company

Developing microbiome-based predictive diagnostic and companion therapeutic products to enable safer and more efficacious drug therapies

Winner of the 2018 European Innovation Quickfire Challenge (read more)